Oculis (NASDAQ:OCS) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Oculis (NASDAQ:OCS) from a strong sell rating to a sell rating in a report issued on Saturday morning.

Other analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Guggenheim cut their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Oculis in a research note on Wednesday. Stifel Nicolaus dropped their target price on Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Robert W. Baird cut their price target on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Trading Up 2.4%

Shares of OCS opened at $12.68 on Friday. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The business has a 50-day moving average of $12.17 and a 200 day moving average of $22.31. The firm has a market cap of $735.19 million, a P/E ratio of -7.29 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 45.58%. As a group, research analysts forecast that Oculis will post -2.22 EPS for the current year.

Institutional Trading of Oculis

A number of hedge funds and other institutional investors have recently bought and sold shares of OCS. China Universal Asset Management Co. Ltd. lifted its stake in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares in the last quarter. Koshinski Asset Management Inc. bought a new position in shares of Oculis in the first quarter worth $238,000. Millennium Management LLC purchased a new position in Oculis during the fourth quarter worth about $312,000. Marshall Wace LLP bought a new position in Oculis in the 2nd quarter worth about $393,000. Finally, Renaissance Technologies LLC bought a new position in Oculis in the 4th quarter worth about $499,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.